Dr Jun Bao, appointed president and CEO of Impact Therapeutics in October 2018, shares his aspirations for Impact to be a leader in synthetic lethality in oncology; the importance of ‘operating locally but selling globally’; his learnings from his distinguished career across biotech and pharma companies in the US and China; and Impact’s portfolio of exciting cancer therapeutics.
Perhaps it has to do with the youth of China's biopharma industry but I find that both Chinese pharma and biotech companies behave more like US biotechs
